Literature DB >> 21903181

Multiple pathways were involved in tubeimoside-1-induced cytotoxicity of HeLa cells.

Yang Xu1, Yick-Pang Ching, Yuan Zhou, Jen-Fu Chiu, Feng Chen, Qing-Yu He.   

Abstract

The Bolbostemma paniculatum (Maxim.) Franquet (Cucurbitaceae) is a Chinese herb with anticancer potential. Its main active component tubeimoside-1 (TBMS1), a triterpenoid saponin, was previously proved as a potent anticancer chemotherapeutic agent; however, the molecular basis for its activities is still elusive. In the present study, subcellular proteomic study in the cytoplasm and membrane protein fractions extracted from HeLa cells revealed that proteins act as mediators of ROS generation and Ca(2+) regulation were substantially altered in expression upon TBMS1 stimuli. We also found that TBMS1 induced cell cycle arrest at G2/M phase accompanied by a decrease in G0/G1 phase in HeLa cells. Further biochemical studies showed that TBMS1 inhibited the levels of cyclinB1, Cdc2 and Cdc25C, but enhanced Chk2 phosphorylation. In addition, the cytoplasm sequestration of Cdc25C, Cip1/p21 induction and tubulin dyspolymerization also contributed to the TBMS1-mediated cell cycle arrest on the G2/M phase.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903181     DOI: 10.1016/j.jprot.2011.08.014

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  9 in total

1.  Tubeimoside-1 induces oxidative stress-mediated apoptosis and G0/G1 phase arrest in human prostate carcinoma cells in vitro.

Authors:  Jing-Bo Yang; Muhammad Khan; Yang-Yang He; Min Yao; Yong-Ming Li; Hong-Wen Gao; Tong-Hui Ma
Journal:  Acta Pharmacol Sin       Date:  2016-06-13       Impact factor: 6.150

2.  Polypeptide Fraction from Arca subcrenata Induces Apoptosis and G2/M Phase Arrest in HeLa Cells via ROS-Mediated MAPKs Pathways.

Authors:  Xianjing Hu; Zhang Zhang; Ting Liu; Liyan Song; Jianhua Zhu; Zhongyi Guo; Jinghua Cai; Rongmin Yu
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-21       Impact factor: 2.629

3.  Anti-proliferative effect of isorhamnetin on HeLa cells through inducing G2/M cell cycle arrest.

Authors:  Juan Wei; Hailan Su; Yang Bi; Jixin Li; Lidan Feng; Wenjun Sheng
Journal:  Exp Ther Med       Date:  2018-02-26       Impact factor: 2.447

4.  Tubeimoside-I sensitizes colorectal cancer cells to chemotherapy by inducing ROS-mediated impaired autophagolysosomes accumulation.

Authors:  Jianghong Yan; Xiaoyun Dou; Jing Zhou; Yuanfeng Xiong; Ling Mo; Longhao Li; Yunlong Lei
Journal:  J Exp Clin Cancer Res       Date:  2019-08-14

Review 5.  Tubeimoside-1: A review of its antitumor effects, pharmacokinetics, toxicity, and targeting preparations.

Authors:  Chang-Lin Wang; Ming-Zhou Gao; Dong-Mei Gao; Ying-Hui Guo; Zhan Gao; Xiang-Ju Gao; Jie-Qiong Wang; Ming-Qi Qiao
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

Review 6.  Chinese endemic medicinal plant Bolbostemma paniculatum (Maxim.) Franquet: A comprehensive review.

Authors:  Yujiao Zhou; Junyu Liu; Jianqiong Zhang; Yi Xu; Wangni Li; Pang Gao; Yanghuan Xing; Lehong Huang; Xuhua Qin; Shenrui Jin
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

7.  Research on the interaction between tubeimoside 1 and HepG2 cells using the microscopic imaging and fluorescent spectra method.

Authors:  Xiaogang Lin; Wenchao Li; Changbin Ye; Xiaozhu Liu; Hao Zhu; Wenbing Peng; Jie Rong
Journal:  Comput Math Methods Med       Date:  2014-05-14       Impact factor: 2.238

8.  Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model.

Authors:  Yuan Gu; Christina Körbel; Claudia Scheuer; Anca Nenicu; Michael D Menger; Matthias W Laschke
Journal:  Oncotarget       Date:  2016-02-02

9.  The effect of tubeimoside-1 on the proliferation, metastasis and apoptosis of oral squamous cell carcinoma in vitro.

Authors:  Tingting Wu; Hongjuan Cui; Yamei Xu; Quangao Du; Erhu Zhao; Jiangjun Cao; Ling Nie; Gang Fu; Aishu Ren
Journal:  Onco Targets Ther       Date:  2018-07-10       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.